TScan Therapeutics (TCRX) Stock Price, Quote, News & History | Benzinga

TScan Therapeutics Inc (TCRX) Stock Price, Quote, News & History

TCRXNASDAQ

Trade with Public

Trade with Public

$0.7710

-0.0537-6.51%

Last update: Aug 19, 9:27 AM

Earnings: Q2 2026 Earnings were released on Wed Aug 12th, before the market open

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Stock Report

Key Statistics

Open

$0.77

Close

-

Volume / Avg.

433.45K / 616.54K

Day Range

$0.77 - $0.82

52 Wk Range

0.72 - 2.57

Market Cap

$52.26M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

42

Short Interest

3.3%

Days to Cover

2.78

Recent TScan Therapeutics Inc News

This Kimberly-Clark Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

Avi Kapoor

Why Is TScan Therapeutics Stock Gaining Today?

TScan Therapeutics' stock rises after announcing a $30 million financing deal with Lynx1, extending its cash runway into 2027.

Nabaparna Bhattacharya

Worthington Steel Posts Upbeat Results, Joins Summit Midstream Partners, FedEx And Other Big Stocks Moving Higher On Friday

U.S. stocks were mixed, with the Dow Jones index falling around 50 points on Friday.

Avi Kapoor

Around $10M Bet On This Real Estate Stock? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying

The Dow Jones closed higher by around 10 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Lisa Levin

Why Nvidia Shares Are Trading Higher By Over 5%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

Gainers QualTek Services Inc. (NASDAQ: QTEK) shares jumped 127.2% to $0.1740 after dropping around 21% on Friday. Qualtek Services recently filed voluntarily petitions for Chapter 11 bankruptcy.

Lisa Levin

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-116.28M

Investing Cash Flow (TTM)

46.87M

Financing Cash Flow (TTM)

172.00K

Free Cash Flow (TTM)

-118.44M

Capital Expenditure (TTM)

-2.16M

Net Change in Cash (TTM)

-69.24M

Analyst Trends and Forecast

1

Mar

2

Jun

1

Aug

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.2

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$46.65M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

15.07

PB Ratio (TTM)

0.81

Earnings Yield % (TTM)

-109.10%

Earnings Yield % (FWD)

-110.32%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$1.02

Company Debt

Total Debt

$32.78M

LT Debt

$21.07M

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$100.16M

Debt to Equity

1.32

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

$0.77

Close

-

Volume / Avg.

433.45K / 616.54K

Day Range

$0.77 - $0.82

52 Wk Range

0.72 - 2.57

Market Cap

$52.26M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

42

Short Interest

3.3%

Days to Cover

2.78

About

Sector

Health Care

Industry

Biotechnology

TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid ...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy TScan Therapeutics (TCRX) stock?

A

You can purchase shares of TScan Therapeutics (NASDAQ:TCRX) through any online brokerage.

View our list of the best stock brokerages

Q

Who are TScan Therapeutics (TCRX) competitors?

A

Other companies in TScan Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Q

What is the forecast, or price target, for TScan Therapeutics (TCRX) stock?

A

TScan Therapeutics has a consensus price target of $8.00.

Q

What is the current price for TScan Therapeutics (TCRX)?

A

The stock price for TScan Therapeutics (NASDAQ: TCRX) is $0.771 last updated August 19, 2026 at 9:27 AM EDT.

Q

Does TScan Therapeutics (TCRX) pay a dividend?

A

There are no upcoming dividends for TScan Therapeutics.

Q

When is TScan Therapeutics (NASDAQ:TCRX) reporting earnings?

A

TScan Therapeutics does not have any upcoming earnings scheduled.

Q

Is TScan Therapeutics (TCRX) going to split?

A

There is no upcoming split for TScan Therapeutics.

Q

What sector and industry does TScan Therapeutics (TCRX) operate in?

A

TScan Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.